BioLineRX
BLRX
26 hedge funds and large institutions have $1.97M invested in BioLineRX in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
30% more funds holding
Funds holding: 20 → 26 (+6)
28% more call options, than puts
Call options by funds: $222K | Put options by funds: $174K
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
32% less capital invested
Capital invested by funds: $2.91M → $1.97M (-$940K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$295K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$116K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$18.8K |
| 4 |
HF
HRT Financial
New York
|
+$18.6K |
| 5 |
GVAG
Great Valley Advisor Group
Wilmington,
Delaware
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$2.02M |
| 2 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$92.6K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$42.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$21.4K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$15.3K |
BLRX Hedge Fund Activity: Q2 2023 in Review
26 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2023, worth a combined $1.97M — down 32% from $2.91M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BLRX positions and 3 closed out — a net gain of 6 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $295K. The largest seller was Altium Capital Management, exiting entirely with an estimated $2.02M sold.
- 26 institutional investors held BioLineRX (BLRX) as of Q2 2023, up from 20 in Q1 2023.
- Funds reported $1.97M of BioLineRX stock for Q2 2023, down 32% quarter-over-quarter.
- 9 funds opened new BioLineRX positions in Q2 2023 and 3 closed out, a net change of +6 holders.
- The largest BioLineRX buyer in Q2 2023 was Citadel Advisors, an estimated $295K added.
- The largest BioLineRX seller in Q2 2023 was Altium Capital Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q2 2023.